Completed PHASE2 INTERVENTIONAL 2-arm NCT00117637

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

Sponsor: Bayer

Conditions Carcinoma, Renal Cell

Interventions Interferon Sorafenib (Nexavar, BAY43-9006)

Updated 7 times since 2017 Last updated: Oct 24, 2014 Started: Jun 30, 2005 Primary completion: Sep 30, 2006 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Renal Cell, this trial is completed. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Berlin, Germany , Bordeaux, France , Chicago, United States , Cleveland, United States , Dallas, United States , Donetsk, Ukraine , Düsseldorf, Germany , Frankfurt am Main, Germany , Frederick, United States and 30 more locations